Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021

This cross-sectional study assesses buprenorphine coverage and prior authorization requirements in US commercial formulary data from 2017 to 2021.

Detalles Bibliográficos
Autores principales: Nguyen, Thuy D., Chua, Kao-Ping, Andraka-Christou, Barbara, Bradford, W. David, Simon, Kosali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270692/
https://www.ncbi.nlm.nih.gov/pubmed/35977219
http://dx.doi.org/10.1001/jamahealthforum.2022.1821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270692/
https://www.ncbi.nlm.nih.gov/pubmed/35977219
http://dx.doi.org/10.1001/jamahealthforum.2022.1821

Ejemplares similares